Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Centessa Pharmaceuticals plc Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023",
"MULTIPLE PATHWAYS TO SIGNIFICANT VALUE CREATION"
07/10/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors Enrollment progressing toward interim analysis planned when 36 subjects reach 12 weeks on treatment in Part 1 of study"
06/09/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "MULTIPLE PATHWAYS TO SIGNIFICANT VALUE CREATION"
05/12/2023 8-K Quarterly results
Docs: "Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023 – Strong clinical momentum and cash runway into 2026 to support multiple clinical readouts across pipeline –"
03/30/2023 8-K Quarterly results
01/27/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Sales Agreement, by and between the Company and SVB Securities LLC",
"Opinion of Goodwin Procter (UK) LLP"
01/26/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors LB101 is a conditionally tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody, being developed for solid tumors"
12/12/2022 8-K Investor presentation
Docs: "Ashley Road, Altrincham, Cheshire, United Kingdom, WA14 2DT,",
"Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension of Phase 2a Study of SerpinPC for Hemophilia"
10/14/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/06/2022 8-K Quarterly results
09/12/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "MULTIPLE PATHWAYS TO SIGNIFICANT VALUE CREATION"
08/10/2022 8-K Quarterly results
Docs: "Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022&#59; Provides Program Update for ZF874 –Registrational studies of SerpinPC for treatment of Hemophilia B planned for 2H of 2022 –"
07/08/2022 8-K Quarterly results
07/01/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors"
06/30/2022 8-K Quarterly results
06/02/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
03/30/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
02/16/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/11/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
12/14/2021 8-K Quarterly results
11/15/2021 8-K Quarterly results
Docs: "Centessa Pharmaceuticals Announces Third Quarter 2021 Financial Results and Business Updates"
11/01/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Centessa Pharmaceuticals Demonstrates Proof-of-Mechanism from First Three PiMZ Subjects Dosed in Part B of Phase 1study Evaluating ZF874 ~ First demonstration that a pharmacological chaperone can provide sufficient functional Z-A1AT increases to potentially achieve greater than 11 micromolar levels in individuals with PiZZ genotype &#126",
"S SPEAKERS GREG WEINHOFF, MD MBA"
10/04/2021 8-K Quarterly results
09/09/2021 8-K Quarterly results
08/16/2021 8-K Quarterly results
Docs: "Centessa Pharmaceuticals Announces Second Quarter 2021 Financial Results and Business Updates ~ Successful completion of an initial public offering of American Depositary Shares raising gross proceeds of $379.5 million to help advance portfolio of 16 clinical and preclinical programs &#126"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy